Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011
Tue, December 27, 2011
Mon, December 26, 2011
Fri, December 23, 2011
Thu, December 22, 2011
Wed, December 21, 2011
Tue, December 20, 2011
[ Tue, Dec 20th 2011 ]: Market Wire
Bard Acquires Lutonix, Inc.

Mylan Receives Approval for First-to-File Generic Keppra XR Extended-Release Tablets

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. -generic-keppra-xr-extended-release-tablets.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Mylan Receives Approval for First-to-File Generic Keppra XR? Extended-Release Tablets -- PITTSBURGH, Dec. 27, 2011 /PRNewswire/ --

Mylan Receives Approval for First-to-File Generic Keppra XR? Extended-Release Tablets

[ ]

Company shares first-to-file marketing exclusivity on all strengths

PITTSBURGH, Dec. 27, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: [ MYL ]) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Extended-release (ER) Tablets, 500 mg and 750 mg. This product is the generic version of UCB's Keppra XR® Tablets, which are a treatment for partial onset seizures in patients over 16 years of age with epilepsy. 

Levetiracetam ER Tablets had U.S. sales of approximately $162.8 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 170 ANDAs pending FDA approval representing $98.4 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $26.8 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit [ www.mylan.com ]. For more information about generic drugs, please visit [ www.ChoosingGenerics.com ].

 

 

SOURCE Mylan Inc.

[ Back to top ]

RELATED LINKS
[ http://www.mylan.com ]